Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN PARP Medley: Avelumab + Talazoparib in Advanced Solid Tumors
NCT03330405Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Oct 2017
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of avelumab, talazoparib in solid tumor, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), Hormone-Receptor-Positive Breast Cancer, ovarian cancer, sponsored by Pfizer. Started Oct 2017; status: terminated.
02
Drugs
avelumabtalazoparib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)Hormone-Receptor-Positive Breast Cancerovarian cancer
Beyond the preview
Go deeper on NCT03330405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03330405.